Xenetic Biosciences, Inc. (XBIO) stock
Close on Nov 11, 2026Market cap $4.37MP/E –Yield –
Xenetic Biosciences, Inc. grew revenue 33.3% to $3.26M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $4.37M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.37M
- P/E ratio
- –
- Price to sales
- 1.34
- Price to book
- 0.72
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.26M
- Net income
- -$2.48M
- EPS, diluted
- -$1.21
- Book value per share
- $2.65
- Diluted shares
- 2M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $1.80
- Open
- $1.77
- Day's range
- $1.77 – $1.90
- Volume
- 3,964
- Average volume (20 days)
- 25,327
- Beta (5 years)
- 0.89
- 52-week range
- $1.58 – $4.94
- RSI (14 days)
- 39.7
- Volatility (1 year)
- 88.1%
- Relative volume
- 0.06×
- WACC
- 9.3%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | XBIO | S&P 500 | Difference | XBIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.4% | -2.4% | −10.0 pts | ||
| 3 months | -42.0% | -1.2% | −40.9 pts | ||
| Year to date | -14.0% | +12.3% | −26.3 pts | ||
| 1 year | -31.6% | +12.4% | −44.1 pts | ||
| 3 years | -35.9% | +78.8% | −114.7 pts | -13.8% | +21.4% |
| 5 years | -88.8% | +75.2% | −164.0 pts | -35.5% | +11.9% |
| 10 years | -99.6% | +311.1% | −410.7 pts | -41.8% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Xenetic Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Results
- Results
About Xenetic Biosciences
Pharmaceutical Preparations
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing immuno-oncology technologies to address difficult-to-treat cancers. Its primary focus is a proprietary deoxyribonuclease (DNase) technology designed to target neutrophil extracellular traps, which are implicated in cancer growth, metastasis, and resistance to standard therapies like chemotherapy and immunotherapy. The company is advancing systemic DNase candidates into clinical development as adjunctive therapies for solid tumors, specifically targeting pancreatic ductal adenocarcinoma and colorectal carcinoma, alongside pre-clinical research into armored CAR T-cell therapies. It also licenses PolyXen, a proprietary drug delivery platform utilizing polysialic acid to improve protein and peptide stability.
Company profile, executives and historyXenetic Biosciences stock: common questions
What is Xenetic Biosciences's stock price?
XBIO closed at $1.87 on Nov 11, 2026, up 3.68% on the day. Over the past 52 weeks it traded between $1.58 and $4.94.
What is Xenetic Biosciences's market cap?
Xenetic Biosciences was worth $4.37M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is XBIO's P/E ratio?
Xenetic Biosciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.21), so it has no meaningful P/E ratio.
How much revenue does Xenetic Biosciences make?
Xenetic Biosciences reported revenue of $3.26M for the twelve months to Jun 30, 2026, up 33.3% from a year earlier.
Does Xenetic Biosciences pay a dividend?
No. Xenetic Biosciences has not paid a cash dividend over the last twelve months.
When does Xenetic Biosciences report earnings next?
Xenetic Biosciences is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has XBIO stock performed over the past year?
Including dividends, XBIO returned -31.6% over the past year, against +12.4% for the S&P 500.
How many XBIO shares are sold short?
0M shares were sold short at the latest FINRA report, 1.80% of the float, or 1.2 days of average trading volume.
Who are Xenetic Biosciences's competitors?
Companies most similar to Xenetic Biosciences by business, industry and size include BOLT, IMNM, MRKR, TRAW, TRDA.
See a number that looks wrong?